학술논문


EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
전자자료 공정이용 안내

우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.

공정이용 지침
  • 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
  • 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
  • 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
  • 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
  • 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
  • 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
  • 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
  • 상업적·영리적 목적으로 자료를 전송·복제·활용
  • ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
  • EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
  • 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
  • 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
  • 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문' 에서 검색결과 15건 | 목록 1~20
Academic Journal
Verronèse E; Innovation in Immuno-monitoring and Immunotherapy Platform (PI3), Léon Bérard Cancer Center , Lyon, France.; Delgado A; Innovation in Immuno-monitoring and Immunotherapy Platform (PI3), Léon Bérard Cancer Center , Lyon, France.; Valladeau-Guilemond J; Team 11, INSERM U1052/CNRS UMR5286, Cancer Research Center of Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, ISPB, Lyon, France.; Garin G; DRCI department, Léon Bérard Cancer Center , Lyon, France.; Guillemaut S; DRCI department, Léon Bérard Cancer Center , Lyon, France.; Tredan O; Department of Medical Oncology, Léon Bérard Cancer Center , Lyon, France.; Ray-Coquard I; Department of Medical Oncology, Léon Bérard Cancer Center , Lyon, France.; Bachelot T; Team 11, INSERM U1052/CNRS UMR5286, Cancer Research Center of Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, ISPB, Lyon, France; Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.; N'Kodia A; Innovation in Immuno-monitoring and Immunotherapy Platform (PI3), Léon Bérard Cancer Center , Lyon, France.; Bardin-Dit-Courageot C; Innovation in Immuno-monitoring and Immunotherapy Platform (PI3), Léon Bérard Cancer Center , Lyon, France.; Rigal C; Innovation in Immuno-monitoring and Immunotherapy Platform (PI3), Léon Bérard Cancer Center , Lyon, France.; Pérol D; DRCI department, Léon Bérard Cancer Center , Lyon, France.; Caux C; Innovation in Immuno-monitoring and Immunotherapy Platform (PI3), Léon Bérard Cancer Center, Lyon, France; Team 11, INSERM U1052/CNRS UMR5286, Cancer Research Center of Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, ISPB, Lyon, France.; Ménétrier-Caux C; Innovation in Immuno-monitoring and Immunotherapy Platform (PI3), Léon Bérard Cancer Center, Lyon, France; Team 11, INSERM U1052/CNRS UMR5286, Cancer Research Center of Lyon, Lyon, France; Université de Lyon, Lyon, France; Université Lyon 1, ISPB, Lyon, France.
Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Print ISSN: 2162-4011 (Print) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: PubMed not MEDLINE
Academic Journal
Trédan O; Departments of Medical Oncology, University Claude Bernard.; Wang Q; Translational Research and Innovation.; Pissaloux D; Translational Research and Innovation.; Cassier P; Medical Oncology.; de la Fouchardière A; BioPathology, Léon Bérard Cancer center, Lyon.; Fayette J; Medical Oncology.; Desseigne F; Medical Oncology.; Ray-Coquard I; Medical Oncology.; de la Fouchardière C; Medical Oncology.; Frappaz D; Medical Oncology.; Heudel PE; Medical Oncology.; Bonneville-Levard A; Medical Oncology.; Fléchon A; Medical Oncology.; Sarabi M; Medical Oncology.; Guibert P; Medical Oncology.; Bachelot T; Medical Oncology.; Pérol M; Medical Oncology.; You B; Department of Medical Oncology, Lyon Sud Hospital Center, CITOHL, Institute of Cancerology, Hospices Civils de Lyon (IC-HCL), Lyon; Faculty of Medicine-Lyon Sud, EMR UCBL/HCL 3738, University of Lyon 1, Oullins.; Bonnin N; Department of Medical Oncology, Lyon Sud Hospital Center, CITOHL, Institute of Cancerology, Hospices Civils de Lyon (IC-HCL), Lyon.; Collard O; Department of Medical Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez.; Leyronnas C; Department of Medical Oncology, Mutualist Hospital Group, Grenoble.; Attignon V; Translational Research and Innovation.; Baudet C; Synergie Lyon Cancer, Bio-Informatics Platform.; Sohier E; Synergie Lyon Cancer, Bio-Informatics Platform.; Villemin JP; Synergie Lyon Cancer, Bio-Informatics Platform.; Viari A; Synergie Lyon Cancer, Bio-Informatics Platform.; Boyault S; Translational Research and Innovation.; Lantuejoul S; BioPathology, Léon Bérard Cancer center, Lyon.; Paindavoine S; BioPathology, Léon Bérard Cancer center, Lyon.; Treillleux I; BioPathology, Léon Bérard Cancer center, Lyon.; Rodriguez C; BioPathology, Léon Bérard Cancer center, Lyon.; Agrapart V; Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France.; Corset V; Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France.; Garin G; Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France.; Chabaud S; Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France.; Pérol D; Department of Clinical Research and Innovation, Léon Bérard Cancer Center, Lyon, France.; Blay JY; Departments of Medical Oncology, University Claude Bernard. Electronic address: jean-yves.blay@lyon.unicancer.fr.
Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Academic Journal
Trédan O; Department of Medical Oncology, Leon Berard Cancer Center, Lyon Lyon University, Lyon ISPB, Lyon 1 University, Lyon CNRS UMR5286, Cancer Research Center of Lyon, Lyon.; Ménétrier-Caux C; Lyon University, Lyon ISPB, Lyon 1 University, Lyon CNRS UMR5286, Cancer Research Center of Lyon, Lyon Innovation in Immuno-monitoring and Immunotherapy Platform (P3I), Leon Berard Cancer Center Team 11, INSERM U1052, Cancer Research Center of Lyon, Lyon.; Ray-Coquard I; Department of Medical Oncology, Leon Berard Cancer Center, Lyon Lyon University, Lyon ISPB, Lyon 1 University, Lyon CNRS UMR5286, Cancer Research Center of Lyon, Lyon isabelle.ray-coquard@lyon.unicancer.fr.; Garin G; Clinical Research Platform (DRCI), Leon Berard Cancer Center, Lyon.; Cropet C; Clinical Research Platform (DRCI), Leon Berard Cancer Center, Lyon.; Verronèse E; Innovation in Immuno-monitoring and Immunotherapy Platform (P3I), Leon Berard Cancer Center.; Bachelot T; Department of Medical Oncology, Leon Berard Cancer Center, Lyon.; Rebattu P; Department of Medical Oncology, Leon Berard Cancer Center, Lyon.; Heudel PE; Department of Medical Oncology, Leon Berard Cancer Center, Lyon.; Cassier P; Department of Medical Oncology, Leon Berard Cancer Center, Lyon.; Chabaud S; Clinical Research Platform (DRCI), Leon Berard Cancer Center, Lyon.; Croughs T; Cytheris SA, Issy-Les-Moulineaux.; Dupont P; Clinical Research Platform (DRCI), Leon Berard Cancer Center, Lyon.; Cadore AC; Clinical Research Platform (DRCI), Leon Berard Cancer Center, Lyon.; Clapisson G; Biological Sample Management Platform (BB-0033-00050).; Delgado A; Innovation in Immuno-monitoring and Immunotherapy Platform (P3I), Leon Berard Cancer Center.; Bardin-dit-Courageot C; Innovation in Immuno-monitoring and Immunotherapy Platform (P3I), Leon Berard Cancer Center.; Rigal C; Innovation in Immuno-monitoring and Immunotherapy Platform (P3I), Leon Berard Cancer Center.; N'Kodia A; Innovation in Immuno-monitoring and Immunotherapy Platform (P3I), Leon Berard Cancer Center.; Gilles-Afchain L; Pharmacy, Leon Berard Cancer Center, Lyon.; Morre M; Revimmune, Paris, France.; Pérol D; Clinical Research Platform (DRCI), Leon Berard Cancer Center, Lyon.; Blay JY; Department of Medical Oncology, Leon Berard Cancer Center, Lyon Lyon University, Lyon ISPB, Lyon 1 University, Lyon CNRS UMR5286, Cancer Research Center of Lyon, Lyon Team 11, INSERM U1052, Cancer Research Center of Lyon, Lyon.; Caux C; Lyon University, Lyon ISPB, Lyon 1 University, Lyon CNRS UMR5286, Cancer Research Center of Lyon, Lyon Innovation in Immuno-monitoring and Immunotherapy Platform (P3I), Leon Berard Cancer Center Team 11, INSERM U1052, Cancer Research Center of Lyon, Lyon.
Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Academic Journal
Publisher: Raven Press Country of Publication: United States NLM ID: 7908071 Publication Model: Print Cited Medium: Print ISSN: 0192-8562 (Print) Linking ISSN: 01928562 NLM ISO Abbreviation: Am J Pediatr Hematol Oncol Subsets: MEDLINE
Academic Journal
Publisher: Country of Publication: Italy NLM ID: 0370611 Publication Model: Print Cited Medium: Print NLM ISO Abbreviation: Athena Subsets: OLDMEDLINE
검색 결과 제한하기
제한된 항목
[AR] Garin, G
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어